Compare Boston Beer Company Inc (SAM) vs 22nd Century Group Inc (XXII) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Boston Beer Company Inc vs 22nd Century Group Inc — how do they compare? Boston Beer Company Inc trades at $170.48 (market cap $1.76B), while 22nd Century Group Inc trades at $0.84 (market cap $621.67K). The key difference: Boston Beer Company Inc is far larger — about 2831.1× 22nd Century Group Inc's market cap, and Boston Beer Company Inc is more actively traded (264,496 versus 45,625). Which is the better fit depends on your goals — on Pluang, investors hold Boston Beer Company Inc for 59 Days and 22nd Century Group Inc for 32 Days on average.
| SAM | XXII | |
|---|---|---|
Market Cap | $1.76B | $621.67K |
Volume | 264,496 | 45,625 |
Sector | Consumer Staples | Consumer Staples |
52-Week High | $260.05 | $483.00 |
52-Week Low | $161.08 | $0.80 |
Typical Hold Time | 59 Days | 32 Days |
Enterprise Value | $1.53B | -$3.69M |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Boston Beer Company (SAM) trades at $171.33, up 1.89% with a bullish technical signal despite mixed earnings performance. The stock shows strong cash flow generation with $270M operating cash flow in 2025, but faces profitability challenges with negative net income margin of -3.64%. Recent developments include new product launches and marketing initiatives targeting younger demographics, while analyst consensus remains cautious with 72% hold ratings.
SAM presents a mixed investment case with attractive valuation metrics (P/E 22.7, P/S 0.94) offset by profitability concerns. Upside potential exists from innovation initiatives and brand investments, but investors face risks from volume declines and competitive pressures. The stock trades near consensus price target of $204.44, suggesting moderate upside if execution improves.
22nd Century Group (XXII) trades at $0.89, down 0.94% today, with a bearish technical signal despite oversold RSI readings. The company shows severe financial stress with negative gross margins of -54.6% and net income margin of -76.01%, though valuation metrics appear low with P/S of 0.09 and P/B of 0.03. Recent news highlights regulatory progress in nicotine reduction initiatives and expanded retail distribution for VLN products.
While analyst consensus remains bullish with 75% buy ratings and a $1,240 price target, fundamental challenges persist with consecutive earnings misses and negative cash flow from operations. The stock presents high-risk speculation on regulatory adoption of reduced-nicotine standards, requiring careful risk assessment given the company's ongoing losses and cash burn.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Boston Beer Company Inc
Boston Beer is a leader in U.S. high-end malt beverages and adjacent categories, with strong positions in craft beer, hard cider, and hard seltzer. The firm sells an array of flavor variants and package sizes, predominantly centered around four priority brands: Samuel Adams, Angry Orchard, Twisted Tea, and Truly Hard Seltzer. Its drinks are produced in both company-owned breweries as well as through third-party contract arrangements, and while the company primarily goes to market through independent wholesalers (as mandated by law), it operates a fairly large salesforce to induce demand across the value chain (distributors, retailers, and drinkers). The preponderance of revenue is generated domestically.
Read more on SAM →About 22nd Century Group Inc
22nd Century Group is a plant biotechnology company that uses genetic engineering and gene editing to control the levels of nicotine in tobacco plants. Its flagship product line, VLN®, is the first and only combustible cigarette authorized by the FDA as a Modified Risk Tobacco Product (MRTP), containing 95% less nicotine than traditional cigarettes to help adult smokers smoke less.
Read more on XXII →
